Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Nov 27;16(22):2748-2762.
doi: 10.1016/j.jcin.2023.08.031.

The Retrograde Approach to Chronic Total Occlusion Percutaneous Coronary Interventions: Technical Analysis and Procedural Outcomes

Salman S Allana  1 , Spyridon Kostantinis  1 , Athanasios Rempakos  1 , Bahadir Simsek  1 , Judit Karacsonyi  1 , Michaella Alexandrou  1 , James W Choi  2 , Khaldoon Alaswad  3 , Oleg Krestyaninov  4 , Dmitrii Khelimskii  5 , Sevket Gorgulu  6 , Rhian Davies  7 , Stewart Benton  7 , Dimitrios Karmpaliotis  8 , Farouc A Jaffer  9 , Jaikirshan J Khatri  10 , Paul Poommipanit  11 , Lorenzo Azzalini  12 , Kathleen Kearney  12 , Raj Chandwaney  13 , William Nicholson  14 , Wissam Jaber  14 , Stephane Rinfret  14 , Jarrod Frizzell  15 , Taral Patel  16 , Brian Jefferson  16 , Nazif Aygul  17 , Bavana V Rangan  1 , Emmanouil S Brilakis  18
Affiliations
Free article
Multicenter Study

The Retrograde Approach to Chronic Total Occlusion Percutaneous Coronary Interventions: Technical Analysis and Procedural Outcomes

Salman S Allana et al. JACC Cardiovasc Interv. .
Free article

Abstract

Background: Retrograde chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with lower success and higher complication rates when compared with the antegrade approach.

Objectives: This study sought to assess contemporary techniques and outcomes of retrograde CTO PCI.

Methods: We examined the baseline characteristics, procedural techniques and outcomes of 4,058 retrograde CTO PCIs performed at 44 centers between 2012 and 2023. Major adverse cardiac events (MACE) included any of the following in-hospital events: death, myocardial infarction, repeat target vessel revascularization, pericardiocentesis, cardiac surgery, and stroke.

Results: The average J-CTO (Multicenter CTO Registry in Japan) score was 3.1 ± 1.1. Retrograde crossing was successful in 60.5% and lesion crossing in 81.6% of cases. The collaterals pathways successfully used were septals in 62.0%, saphenous vein grafts in 17.4%, and epicardials in 19.1%. The technical and procedural success rates were 78.7% and 76.6%, respectively. When retrograde crossing failed, technical success was achieved in 50.3% of cases using the antegrade approach. In-hospital MACE was 3.5%. The clinical coronary perforation rate was 5.8%. The incidence of in-hospital MACE with retrograde true lumen crossing, just marker antegrade crossing, conventional reverse controlled antegrade and retrograde tracking (CART), contemporary reverse CART, extended reverse CART, guide-extension reverse CART, and CART was 2.1%, 0.8%, 5.5%, 3.0%, 2.1%, 3.2%, and 4.1%, respectively; P = 0.01).

Conclusions: Retrograde CTO PCI is utilized in highly complex cases and yields moderate success rates with 5.8% perforation and 3.5% periprocedural MACE rates. Among retrograde crossing strategies, retrograde true lumen puncture was the safest. There is need for improvement of the efficacy and safety of retrograde CTO PCI.

Keywords: coronary artery disease; coronary chronic total occlusion; percutaneous coronary intervention; retrograde.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The Minneapolis Heart Institute Foundation; Science Center for Coronary Artery Disease (CCAD) helped support this research project. Study data were collected and managed using Research Electronic Data Capture. (REDCap) electronic data capture tools hosted at the Minneapolis Heart Institute Foundation (MHIF), Minneapolis, Minnesota. Dr Allana has been a consultant for Boston Scientific and Abiomed. D. Choi has received speaking honoraria from Shockwave. Dr Alaswad has been a consultant and speaker for Boston Scientific, Abbott Cardiovascular, Teleflex, and Cardiovascular Systems Inc. Dr Davies has received speaking honoraria from Abiomed, Asahi Intec, Boston Scientific, Medtronic, Siemens Healthineers, Shockwave, and Teleflex; and has served on advisory boards for Abiomed, Boston Scientific, Medtronic, and Rampart. Dr Karmpaliotis has received honoraria from Boston Scientific, Abbott Vascular, Abiomed; Equity: Saranas, Soundbite, and Traverse Vascular. Dr Jaffer has received research funding from Canon, Siemens, Shockwave, Teleflex, Mercator, Boston Scientific, HeartFlow, and Amarin; has been a consultant for Boston Scientific, Siemens, Magenta Medical, International Medical Device Solutions, Asahi Intecc, Biotronik, Philips, Intravascular Imaging, and DurVena; holds equity interest in Intravascular Imaging Inc, Massachusetts General Hospital, and DurVena; and has licensing arrangements with Terumo, Canon, and Spectrawave, for which he hast he right to receive royalties. Dr Khatri has received honoraria for proctoring and speaking from Abbott Vascular, Medtronic, Terumo, and Shockwave Medical. Dr Poommipanit has been a consultant for Medtronic, Asahi Intecc, and Abbott Vascular. Dr Azzalini has received consulting fees from Teleflex, Abiomed, GE Healthcare, Asahi Intecc, Philips, Abbott Vascular, Reflow Medical, and Cardiovascular Systems, Inc. Dr Nicholson has been a proctor and is on Speakers Bureau and advisory boards for Abbott Vascular, Boston Scientific, and Asahi Intecc; and holds intellectual property with Vascular Solutions. Dr Jaber has received consulting fees from Inari Medical and Medtronic. Dr Rinfret has been a consultant for Boston Scientific, Teleflex, Medtronic, Abbott, and Abiomed. Dr Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (as associate editor of Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), ControlRad, CSI, Elsevier, GE Healthcare, IMDS, InfraRedx, Medicure, Medtronic, Opsens, Siemens, and Teleflex; has received research support from Boston Scientific and GE Healthcare; is the owner of Hippocrates LLC; and is a shareholder in MHI Ventures, Cleerly Health, and Stallion Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Comment in

Publication types

MeSH terms

LinkOut - more resources